RxDoctor Payments Data

Jeffrey Sanders, MD

Family Medicine · Carson City, NVNPI 1386605400

Payments from drug & device makers

$522in general payments, 2019–2025

Across 23 payments — averaging $22.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$150
  • GSK$61
  • Johnson & Johnson$53
  • Pfizer$45
  • AbbVie$43
  • Novartis$37
  • plus $133 from 7 others

What the payments were for

  • Food & beverage$522100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$522 in reported general payments places this provider in the 55th percentile of 902 family medicine providers in Nevada.

See all family medicine providers in Nevada

Medicare billing

Part B allowed, 2024
$217,418
Medicare patients
443
Services billed
3,480

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban90$87,884
OzempicSemaglutide65$62,963
TrulicityDulaglutide40$57,412
MounjaroTirzepatide31$34,282
JanuviaSitagliptin Phosphate18$29,785
XareltoRivaroxaban19$26,346
JardianceEmpagliflozin15$22,111
Humalog Kwikpen U-200Insulin Lispro15$21,745
Lantus SolostarInsulin Glargine,hum.Rec.Anlog37$7,940
SynthroidLevothyroxine Sodium67$7,363
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog14$6,692
Pregabalin16$4,685
SymbicortBudesonide/Formoterol Fumarate14$3,809
Wixela InhubFluticasone Propion/Salmeterol19$3,535
Potassium Chloride120$3,495

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$45$89,313103 claims
Novo NordiskOzempic$31$62,96365 claims
Johnson & JohnsonXarelto$53$26,34619 claims
AbbVieSynthroid$43$7,36367 claims
AstraZenecaSymbicort$20$3,80914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 902 family medicine providers in Nevada.

Other family medicine in Carson City

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →